Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) navigation Ann Rheum Dis Actions . 2020 Dec 11;annrheumdis-2020-218758. doi: 10.1136/annrheumdis-2020-218758. Online ahead of print. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands. 2 Division of Pharmacoepidemiology

The effect of physical exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis The effect of physical exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest (...) exercise on rheumatoid arthritis: An overview of systematic reviews and meta-analysis , , , , Affiliations Expand Affiliations 1 School of Nursing, Peking University, Beijing, P.R. China. 2 Department of Rheumatology and Immunology, The People's Hospital of Peking University, Beijing, P.R. China. 3 Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, P.R. China. 4 Health Science Centre for Evidence-Based Nursing: A Joanna Briggs Institute Centre of Excellence, Peking

Upadacitinib for treating severe rheumatoid arthritis Upadacitinib for treating severe rheumatoid arthritis T echnology appraisal guidance Published: 9 December 2020 www.nice.org.uk/guidance/ta665 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Upadacitinib for treating severe rheumatoid arthritis (TA665) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about upadacitinib 7 Marketing authorisation 7 Dosage in the marketing authorisation 7 Price 7 3 Committee

Non-surgical Periodontal Treatment in Individuals with Periodontal Disease and Rheumatoid Arthritis (RA) Leads to Improvements in Markers of RA Disease Activity UTCAT3453, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Non-surgical Periodontal Treatment in Individuals with Periodontal Disease and Rheumatoid Arthritis (RA) Leads to Improvements in Markers of RA Disease Activity Clinical Question For patients (...) with rheumatoid arthritis (RA) and periodontal disease (PD), does non-surgical periodontal therapy impact the patient’s rheumatic health based on biochemical and clinical parameters of RA? Clinical Bottom Line With non-surgical periodontal treatment in patients with RD and RA, there is a positive effect on multiple biochemical and clinical parameters of RA; this conclusion is based on the results of three systematic reviews. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) of print. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme , , , , , , , , , , Affiliations Expand Affiliations 1 Metroplex Clinical Research Center, Dallas, Texas, USA arthdoc@aol.com. 2 Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands. 3 Oregon Health and Science University, Portland, Oregon, USA. 4 Centro Universitario Central Paulista, São Paulo, Brazil. 5 University of Occupational and Environmental

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naive Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Arthritis Rheumatol Actions . 2020 Jul 8;72(10):1607-1620. doi: 10.1002/art.41384. Online ahead of print. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Randomized, Double-blind, Active-comparator, Multi-center, Multi-country Trial , , , , , , , , , Affiliations Expand Affiliations

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) . Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study) , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Metroplex Clinical Research Center, Dallas, TX, USA. 2 Genentech, Inc, South San Francisco, CA, USA. 3 Division of Immunology and Rheumatology, Stanford University, Stanford, CA, USA. 4 Centro Médico Privado De Reumatología, Tucumán, Argentina. 5 University of Belgrade Medical School, Belgrade, Serbia. 6 Bogomolets

Filgotinib (Jyseleca) - rheumatoid arthritis Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/420605/2020 EMEA/H/C/005113 Jyseleca (filgotinib) An overview of Jyseleca and why (...) it is authorised in the EU What is Jyseleca and what is it used for? Jyseleca is a medicine for treating adults with moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue to cause inflammation and pain in joints. Jyseleca is used alone or with another medicine, methotrexate, after treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or causes unacceptable side effects. DMARDs

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain.To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy.Retrospective cohort (...) associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk.National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis Infections in baricitinib clinical trials for patients with active rheumatoid arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Oct;79(10):1290-1297. doi: 10.1136/annrheumdis-2019-216852. Epub 2020 Aug 11. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) navigation Ann Rheum Dis Actions . 2020 Aug 5;annrheumdis-2019-216761. doi: 10.1136/annrheumdis-2019-216761. Online ahead of print. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Rheumatology Clinical Research Division, Swedish Medical Center/Providence St. Joseph Health and University

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) : 10.1093/rheumatology/keaa234. Online ahead of print. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Rheumatology, Medical University of Vienna, Vienna, Austria. 2 Department of Rheumatology, Metroplex Clinical Research Center, Dallas, TX, USA. 3 Department of Internal Medicine, Rheumatology/Clinical Immunology, University Hospital

Rituximab (Riximyo) - Non?Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis Evidence summary Published: 21 July 2020 www.nice.org.uk/guidance/es29 pathways Product overview Product overview The content of this evidence summary was up-to-date in July 2020. See summaries of product characteristics (SPCs), British National Formulary (BNF) or the Medicines and Healthcare products Regulatory (...) Agency (MHRA) or NICE websites for up-to-date information. Remsima for subcutaneous injection (Celltrion Healthcare Hungary Kft) is a biosimilar monoclonal antibody of infliximab that inhibits the activity of tumour necrosis factor (TNF)-alpha. It has a marketing authorisation for managing rheumatoid arthritis in combination with methotrexate. Likely place in therapy Likely place in therapy As with all biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Remsima

Rituximab (Ruxience) - Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared (...) with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis.The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day

Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. To assess the comparative effectiveness of biological medicines in rheumatoid arthritis in sufficiently similar patient populations, based on the current definitions of key outcomes.Systematic review and network meta-analysis including aggregate results from reanalysed individual patient data.Clinical study (...) reports and aggregate results from reanalyses of individual patient data on key outcomes for rheumatoid arthritis provided by study sponsors for studies conducted up to 2017, and several databases and registries from inception up to February 2017.Randomised controlled trials investigating patient relevant outcomes in adults with rheumatoid arthritis treated with biological medicines in combination with methotrexate after methotrexate failure for at least 24 weeks.45 eligible trials were identified

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab Implication of Baseline Levels and Early Changes of C-reactive Protein for Subsequent Clinical Outcomes of Patients With Rheumatoid Arthritis Treated With Tocilizumab - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Jul;79(7):874-882. doi: 10.1136/annrheumdis-2019-215987. Epub 2020 May 5. Implication of Baseline Levels and Early Changes of C-reactive Protein for Subsequent Clinical Outcomes of Patients With Rheumatoid Arthritis Treated With Tocilizumab , , , Affiliations Expand Affiliations

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study Efficacy and Safety of Upadacitinib in Japanese Patients With Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-Controlled Phase IIb/III Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions . 2020 Apr 11;keaa084. doi: 10.1093/rheumatology/keaa084. Online ahead of print. Efficacy and Safety of Upadacitinib in Japanese Patients With Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-Controlled Phase IIb/III Study , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, Toho University

Upadacitinib (Rinvoq) - rheumatoid arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012